A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Inclusion Criteria

• •History of chronic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) (2018) for at least 6 months as of Visit 1.
• •During the last 28 days of the screening/baseline period, and as per eDiary:
• •* Participant must have completed the eDiary for a minimum of 20 out of 28 days.
• •* Participant has \>= 15 headache days.
• •* Participant has \>= 8 migraine days.